Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,399 result(s) found. Displaying page 2,139 of 2,220.
    EudraCT Number: 2010-024604-10 Sponsor Protocol Number: S52898 Start Date*: 2011-03-18
    Sponsor Name:UZ Gasthuisberg Leuven
    Full Title: An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escala...
    Medical condition: Polycystic liver disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048834 Polycystic liver disease LLT
    12.1 10048834 Polycystic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000541-41 Sponsor Protocol Number: N/A Start Date*: 2021-04-22
    Sponsor Name:Oslo University Hospital
    Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial
    Medical condition: SARS-CoV-2- infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005458-27 Sponsor Protocol Number: MK-4830-002 Start Date*: 2022-04-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
    Medical condition: First-line treatment of advanced High Grade Serous Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001998-24 Sponsor Protocol Number: ME3827/1-1 Start Date*: 2014-10-09
    Sponsor Name:Saarland University
    Full Title: A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5...
    Medical condition: Preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003407-35 Sponsor Protocol Number: SL0044 Start Date*: 2022-03-09
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Prematurely Ended) FR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) PT (Prematurely Ended) AT (Completed) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002638-18 Sponsor Protocol Number: 20190288 Start Date*: 2021-10-14
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment
    Medical condition: KRAS p.G12C mutant untreated stage IV Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended) DE (Temporarily Halted) BE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) DK (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004908-36 Sponsor Protocol Number: RAD001A B253 E03 Start Date*: 2007-01-10
    Sponsor Name:Novartis Farmaceútica S.A
    Full Title: Extension E-03 al Protocolo nº RAD001AB253 Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la med...
    Medical condition: Trasplante cardiaco de novo
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003279-38 Sponsor Protocol Number: TZP-101-CL-G004 Start Date*: 2007-08-17
    Sponsor Name:Tranzyme Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe G...
    Medical condition: TZP-101 will be developed as a first-in class therapy for the treatment of gastric dysmotility.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005356-25 Sponsor Protocol Number: 12712A Start Date*: 2016-07-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) PL (Completed) IT (Prematurely Ended) ES (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001623-44 Sponsor Protocol Number: IRON-CRT-001 Start Date*: 2017-06-15
    Sponsor Name:Ziekenhuis Oost Limburg (ZOL), Genk
    Full Title: Effect of Intravenous Ferric Carboxymaltose on reverse remodeling following Cardiac Resynchronization therapy
    Medical condition: Heart failure with reduced left ventricular ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004496-31 Sponsor Protocol Number: CNTO148UCO3003 Start Date*: 2018-11-07
    Sponsor Name:Janssen Biologics BV
    Full Title: A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety,and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Pa...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) FR (Trial now transitioned) NL (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005269-15 Sponsor Protocol Number: CO42865 Start Date*: 2022-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER
    Medical condition: RET-mutated Medullary Thyroid Cancer (MTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) BG (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006486-38 Sponsor Protocol Number: ComplexitDOC_PSI Start Date*: 2022-08-17
    Sponsor Name:University of Liege
    Full Title: Complexity-enhancing drugs to treat disorders of consciousness (DoC): a psilocybin study
    Medical condition: Disorders of consciousness as unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) after a coma due to acquired brain injury.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005651-17 Sponsor Protocol Number: plexusogsirkulasjon Start Date*: 2013-06-13
    Sponsor Name:Oslo Universitetssykehus
    Full Title: Plexus brachialis block and circulation. Comparing effects on skin microcirculation and macro circulation of lidocain brachial plexus block with versus without epinephrine.
    Medical condition: human microcirculation and haemodynamic changes (macrosirculation) in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001656-18 Sponsor Protocol Number: INOCOV-19 Start Date*: 2020-05-19
    Sponsor Name:Oslo University Hospital
    Full Title: Inhaled Nitric Oxide As A Bridge To Mechanical Ventilation In Patients With Suspected Covid-19 Respiratory Failure
    Medical condition: Severe respiratory failure in patients with confirmed, suspected or probable Covid- 19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001165-21 Sponsor Protocol Number: CHDM201I12201 Start Date*: 2022-02-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005221-12 Sponsor Protocol Number: OCTOPUS-2014 Start Date*: 2015-09-07
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. The University of Glasgow
    Full Title: OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001798-21 Sponsor Protocol Number: GS-US-558-5915 Start Date*: 2022-01-27
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-002434-40 Sponsor Protocol Number: AST-MOMA Start Date*: 2012-03-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis Modification according to manifestation
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002585-12 Sponsor Protocol Number: A3L00057 Start Date*: 2020-08-03
    Sponsor Name:SANOFI PASTEUR
    Full Title: Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants
    Medical condition: Haemophilus influenzae type b immunisation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    21.1 10042613 - Surgical and medical procedures 10069533 Haemophilus influenzae type b immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 15 02:54:54 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA